Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib plus trametinib for BRAF-mutant melanoma with brain metastases
2013-003452-21Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in melanoma (2 cohorts), sponsored by GSK. Primary endpoint: Intracranial response. Started Dec 2013; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-003452-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003452-21.